Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes

Heart failure with reduced ejection fraction (HFrEF) is increasingly treated with medications for type 2 diabetes mellitus (T2DM). Whether metabolic derangements in HFrEF and T2DM are associated with differential outcomes remains unclear. Therefore, understanding molecular pathways in HFrEF and T2DM...

Descripción completa

Detalles Bibliográficos
Autores principales: Lerman, Joseph B., Giamberardino, Stephanie N., Hernandez, Adrian F., Felker, G. Michael, Shah, Svati H., McGarrah, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163122/
https://www.ncbi.nlm.nih.gov/pubmed/35654972
http://dx.doi.org/10.1038/s41598-022-12973-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163122/
https://www.ncbi.nlm.nih.gov/pubmed/35654972
http://dx.doi.org/10.1038/s41598-022-12973-0

Ejemplares similares